Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations

In the absence of specific therapy, the 15%–20% of breast cancers demonstrating human epidermal growth-factor receptor 2 (HER2) protein overexpression and/or gene amplification are characterized by a more aggressive phenotype and poorer prognosis compared to their HER2-negative counterparts. Trastuz...

Descripción completa

Detalles Bibliográficos
Autores principales: Lamond, Nathan WD, Younis, Tallal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037302/
https://www.ncbi.nlm.nih.gov/pubmed/24876795
http://dx.doi.org/10.2147/IJWH.S47357

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037302/
https://www.ncbi.nlm.nih.gov/pubmed/24876795
http://dx.doi.org/10.2147/IJWH.S47357

Ejemplares similares